Versiones
- 13-01-2021 (5)
- 13-01-2021 (4)
- 13-01-2021 (3)
- 18-12-2020 (2)
- 18-12-2020 (1)
Palabras clave
asma grave
anticuerpos monoclonales
biológicos
asma grave eosinofílica
Resumen
El asma grave es una enfermedad heterogénea y compleja que afecta aproximadamente al 5% de los pacientes con asma y se asocia a una importante carga de síntomas, exacerbaciones graves frecuentes e impactos negativos en la funcionalidad y calidad de vida. Diferentes estrategias de innovación han actualizado las opciones terapéuticas disponibles para estos pacientes, pero los anticuerpos monoclonales representan las alternativas con mayor relevancia clínica. Como especialistas en asma es importante mantenernos actualizados para poder identificar correctamente a aquellos pacientes que pueden beneficiarse del tratamiento con estos medicamentos. Este artículo ofrece una revisión actualizada y práctica enfocada en mepolizumab, un anticuerpo monoclonal humanizado anti-IL5 aprobado como tratamiento complementario en pacientes con asma grave eosinofílica. Los autores hemos realizado una síntesis de las evidencias de eficacia, seguridad y efectividad de mepolizumab con el objetivo de proveer una herramienta de consulta y apoyo en la toma de decisiones para el especialista que evalúa, diagnostica y trata pacientes con asma grave. Mepolizumab ha documentado en condiciones controladas de ensayos clínicos, y en estudios de vida real reducir consistente y significativamente las exacerbaciones de asma, mejorar el control de la enfermedad, mejorar la calidad de vida de los pacientes, y disminuir la dosis o retirar la exposición a corticoesteroides sistémicos.
Referencias
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73. doi: 10.1183/09031936.00202013. PubMed PMID: 24337046.
Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000;162(6):2341-51. doi: 10.1164/ajrccm.162.6.ats9-00. PubMed PMID: 11112161.
W B. Definition and Impact. Severe Asthma. Wakefield, United Kingdom: European REspiratory Society; 2019. p. 1-15.
McDonald VM KE, Hyland ME,. Understanding the experience of people living with severe asthma. ERS Monograph Severe Asthma. Wakefield, United Kingdom: European Respiratory Society; 2019. p. 16-29.
Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med. 2006;100(3):434-50. doi: 10.1016/j.rmed.2005.06.012. PubMed PMID: 16099149.
Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-43. doi: 10.1016/S0140-6736(06)69283-0. PubMed PMID: 16935684.
Menezes AM HP, Montes-de-Oca M, Muiño A, Lopez MV, et.al. Prevalence of asthma in Latin American middle-aged and older adults and its overlap with diagnosis of COPD. European Respiratory Journal. 2011;38:4136.
The Global Asthma Report 20182020 3 7. Available from: http://www.globalasthmareport.org/Global%20Asthma%20Report%202018.pdf.
Instituto Nacional de Estadística GeI. Población: INEGI; 2020 [updated 2015; cited 2020 7 marzo 2020]. Available from: https://www.inegi.org.mx/temas/estructura/default.html#Informacion_general.
Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1). doi: 10.1183/13993003.00588-2019. PubMed PMID: 31558662.
Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902. doi: 10.1016/j.jaci.2014.08.042. PubMed PMID: 25441637.
Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma [Internet]. 2020. Available from: www.ginasthma.org.
British guideline on the management of asthma. Health Improvement Scotland | SIGN [Internet]. 2019. Available from: https://www.sign.ac.uk/sign-158-british-guideline-on-the-management-of-asthma.
GEMA4.4. Guía española para el manejo del asma. GEMA44 Guía española para el manejo del asma [Internet]. 2019. Available from: https://www.gemasma.com/.
Guidelines for the Diagnosis and Management of Asthma (EPR-3). Guidelines for the Diagnosis and Management of Asthma (EPR-3) [Internet]. 2007. Available from: https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma.
Larenas-Linnemann D S-HJ, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, et.al. Guía Mexicana del Asma: GUIMA 2017. Revista Alergia México. 2017;64(Supl 1):S11-S128.
WW B. Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 2019;68(2):158–66.
Greenfeder S US, Cuss FM, Chapman RW, Egan RW,. Th2 cytokines and asthma — The role of interleukin-5 in allergic eosinophilic disease. Respir Res. 2001;2(2):71-9.
GSKPRO. Indicación Para Prescribir Amplia - Nucala [Internet]. 2016 06 02. Available from: https://gskpro.com/content/dam/global/hcpportal/es_MX/protected/products/Nucala/Pdf/IPP-A-Nucala-GDS05_IPI05-02-Jun-2016.pdf.
Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218-24. doi: 10.1164/rccm.200711-1754OC. PubMed PMID: 18480428; PubMed Central PMCID: PMCPMC3992366.
de Carvalho-Pinto RM, Cukier A, Angelini L, et al. Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med. 2012;106(1):47-56. doi: 10.1016/j.rmed.2011.08.013. PubMed PMID: 21890336.
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X. PubMed PMID: 22901886.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-207. doi: 10.1056/NEJMoa1403290. PubMed PMID: 25199059.
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-97. doi: 10.1056/NEJMoa1403291. PubMed PMID: 25199060.
Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390-400. doi: 10.1016/S2213-2600(17)30125-X. PubMed PMID: 28395936.
Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549-56. doi: 10.1016/S2213-2600(16)30031-5. PubMed PMID: 27177493.
Humbert M, Albers FC, Bratton DJ, et al. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respir Med. 2019;154:69-75. doi: 10.1016/j.rmed.2019.06.004. PubMed PMID: 31220806.
Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-51 e7. doi: 10.1016/j.jaci.2018.09.033. PubMed PMID: 30359681.
Lugogo N, Domingo C, Chanez P, et al. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clin Ther. 2016;38(9):2058-70 e1. doi: 10.1016/j.clinthera.2016.07.010. PubMed PMID: 27553751.
Khurana S BG, Bel EH, FitzGerald JM, Masoli M, et.al. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics. 2019;41(10):2041-56.
Jeimy S, Tsoulis MW, Hachey J, et al. Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective. Allergy Asthma Clin Immunol. 2018;14(68):68. doi: 10.1186/s13223-018-0301-6. PubMed PMID: 30479629; PubMed Central PMCID: PMCPMC6249851.
Menzella F, Galeone C, Ruggiero P, et al. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study. Pulm Pharmacol Ther. 2020;60(101874):101874. doi: 10.1016/j.pupt.2019.101874. PubMed PMID: 31857207.
Cockle SM, Stynes G, Gunsoy NB, et al. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison. Respir Med. 2017;123:140-8. doi: 10.1016/j.rmed.2016.12.009. PubMed PMID: 28137490.
Nachef Z KA, Mashtare T, Zhuang T, Jeffery M,. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network metaanalysis. Journal of Asthma. 2018;55(1):89-100.
Wang FP, Liu T, Lan Z, et al. Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(11):e0166833. doi: 10.1371/journal.pone.0166833. PubMed PMID: 27875559; PubMed Central PMCID: PMCPMC5119789.
Farne HA WA, Powell C, Bax L, Milan SJ,. Anti-IL5 therapies for asthma (Review). Cochrane Database of Systematic Reviews. 2017(9):1-102.
He LL, Zhang L, Jiang L, et al. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis. Int Immunopharmacol. 2018;64:223-31. doi: 10.1016/j.intimp.2018.08.031. PubMed PMID: 30199847.
Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018;52(5). doi: 10.1183/13993003.01393-2018. PubMed PMID: 30309978; PubMed Central PMCID: PMCPMC6277255.
Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097. doi: 10.1080/20018525.2018.1536097. PubMed PMID: 30533206; PubMed Central PMCID: PMCPMC6282428.
Yan K, Balijepalli C, Sharma R, et al. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. Immunotherapy. 2019;11(17):1491-505. doi: 10.2217/imt-2019-0113. PubMed PMID: 31686556.
Casale TB, Pacou M, Mesana L, et al. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. J Allergy Clin Immunol Pract. 2019;7(1):122-30 e1. doi: 10.1016/j.jaip.2018.08.036. PubMed PMID: 30217529.
Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190-200 e20. doi: 10.1016/j.jaci.2018.08.031. PubMed PMID: 30205189.
Iftikhar IH, Schimmel M, Bender W, et al. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis. Lung. 2018;196(5):517-30. doi: 10.1007/s00408-018-0151-5. PubMed PMID: 30167841.
Edris A, De Feyter S, Maes T, et al. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179. doi: 10.1186/s12931-019-1138-3. PubMed PMID: 31395084; PubMed Central PMCID: PMCPMC6688359.
Calzetta L MM, Rogliani P,. Monoclonal antibodies in severe asthma: is it worth it? Expert Opinion on Drug Metaboilsm & Toxicology. 2019;15(6):517-20.
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-42. doi: 10.1111/all.14221. PubMed PMID: 32034960.
Ramonell RP, Iftikhar IH. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis. Lung. 2020;198(1):95-103. doi: 10.1007/s00408-019-00310-8. PubMed PMID: 31894410.
Eichler HG, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10(7):495-506. doi: 10.1038/nrd3501. PubMed PMID: 21720406.
Hernández-Martin I BP, Sanchez-Jareño M, Palao-Ocharan P, Domínguez-Ortega J, et.al, editor Patients with severe eosinophilic asthma treated with Mepolizumab: Results from our clinical practice. 2019 AAAAI Annual Meeting; 2019; San Francisco.
Feijoo P ea, editor Clinical utility of mepolizumab in real-life practice in severe asthma unit of Madrid (Spain). EAACI Congress 2018; 2018; Munich.
Kurosawa M, Sutoh E. Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma. J Investig Allergol Clin Immunol. 2019;29(1):40-5. doi: 10.18176/jiaci.0285. PubMed PMID: 29957591.
Bjerrum AS SJ, Skjold T,, editor OralOral glucocorticoid-sparing effects of mepolizumab. A real-life study. ERS 2018 Congress; 2018; Paris.
Bjerrum AS ST, Schmidt J,, editor Baseline characteristics of 36 mepolizumab-patients. Experiences from the clinical practice. ERS Congress; 2017; Milan.
Farah CS, Badal T, Reed N, et al. Mepolizumab improves small airway function in severe eosinophilic asthma. Respir Med. 2019;148:49-53. doi: 10.1016/j.rmed.2019.01.016. PubMed PMID: 30827474.
Seccombe L RP, Reed N, Badal T, Thamrin C, et.al, editor Mepolizumab improves small airway function in severe eosinophilic asthma. ERS Congress; 2018; Paris.
d’Ancona G LB, WeiL, Green L, Fernandes M, et.al, editor S81 Does adherence to inhaled therapy change following initiation of mepolizumab in the treatment of severe asthma? BTS Winter Meeting; 2018; London.
Llanos JP, Bell CF, Packnett E, et al. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study. J Asthma Allergy. 2019;12:43-58. doi: 10.2147/JAA.S189676. PubMed PMID: 30774390; PubMed Central PMCID: PMCPMC6354698.
Ortega H HB, Tran JN, Bell C, Shams SA, et.al. Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study. Allergy Asthma Proc. 2019;40(3):146-53.
LaHood NA RL, Long AA,, editor Clinical Indication and Outcomes of Mepolizumab Therapy at an Academic Medical Center. 2019 AAAAI Annual Meeting; San Francisco.
Weir E PJ. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience. J Asthma. 2020;57(5):521-4.
Zhang P VC, Wenzel SE,, editor Real World Effectiveness and Safety of Anti-IL-5/Mepolizumab in an Academic Severe Asthma Clinic. ATS International Conference 2017; 2017; Washington.
Kavanagh J GL, Fernandes M, Bolton M, d'Ancona G,, editor Assessment of Early Responder Characteristics to Mepolizumab in Steroid-Dependent Eosinophilic Asthma. ATS International Conference; 2018; San Diego.
Harrison T CG, Gemzoe K, Maxwell A, Yang S, et. al, editor Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study. ERS 2019; 2019; Madrid.
Strauss RA, Jawhari N. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field. Ann Allergy Asthma Immunol. 2018;121(1):121-3. doi: 10.1016/j.anai.2018.04.016. PubMed PMID: 29684570.
Benjamin MR BB, Peters AT,. Mepolizumab use: Post-approval academic practice experience. Ann Allegy Asthma. 2018;121(1):126-8.
Gruber A TC, Chanez P, Devouassoux G, Didier A, et.al, editor Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma. ERS Congress; 2019; Madrid.
Pelaia C, Busceti MT, Solinas S, et al. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study. Pulm Pharmacol Ther. 2018;53:1-5. doi: 10.1016/j.pupt.2018.09.006. PubMed PMID: 30217438.
Venkata MS SD, McCarroll S, Micklewright S, Ibrahim L, et.al, editor Mepolizumab treatment in Severe Asthma: A Case Series. ATS 2017; 2017; Washington.
Hahn B L-AJ, Ortega H, Packnett E, Irwin D, et.al, editor Disease Severity and Baseline Characteristics of Patients Receiving Mepolizumab or Omalizumab in Employer Claims Database: A real-world experience. 2018 AAAAI/WAO Joint Congress; 2018; Orlando.
Bagnasco D, Milanese M, Rolla G, et al. The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials. World Allergy Organ J. 2018;11(1):34. doi: 10.1186/s40413-018-0210-7. PubMed PMID: 30555618; PubMed Central PMCID: PMCPMC6282342.
Antonicelli L ea, editor Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody. ERS 2018; 2018; Paris.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2020 Revista Alergia México